|Videos|September 20, 2021
Latest Treatment Updates in Cervical Cancer
Pharmacy Times spoke with Dr. Bradley Monk, investigator for KEYNOTE-826, #LBA2, which was presented at the ESMO Congress 2021, about the study and its importance to the world of cervical cancer.
Advertisement
Pharmacy Times spoke with Dr. Bradley Monk, investigator for KEYNOTE-826, #LBA2, which was presented at the ESMO Congress 2021, about the study and its importance to the world of cervical cancer.
Dr. Monk discussed the highlights of the study, limitations and gaps, and what he feels were the most important findings of the study in the interview.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Related Content
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
What Pharmacists Should Know About Most Favored Nation as Drug Prices Continue to Rise
2
Positive Phase 2a Trial Supports FDA Clearance of StemCyte’s HPC Therapy for Long COVID Patients
3
From Underdiagnosed to Under Control: Plozasiran and Pharmacists’ Role in FCS
4
FDA Grants Orphan Drug Designation to Zavabresib for the Treatment of Myelofibrosis
5